fbpx

Alzheimer Revolution – Sitografia e Bibliografia

ALZHEIMER REVOLUTION

Sitografia e bibliografia del nuovo libro di Maria Teresa Ferretti Alzheimer Revolution, suddivise per capitoli

Introduzione

1. Una timeline della ricerca sull’Alzheimer: www.alzforum.org

Capitolo 1 – Alzheimer non vuol dire demenza: una nuova definizione molecolare della malattia

  1. Still Alice, Lisa Genova, Ed. Simon & Schuster Ltd, 2012 (traduzione di Maria Teresa Ferretti)
  2. McKahn et al., The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimer’s and Dementia, 2011
  3. Per una panoramica sui vari tipi di demenza: www.alz.org
  4. Jack et al., NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease, Alzheimer’s and Dementia 2018
  5. Alzheimer’s Disease International, World Alzheimer Report 2019, Attitudes to dementia; London

Capitolo 2 – La malattia di Alzheimer comincia decenni prima dei sintomi, ed è una buona notizia

  1. Anna Karenina, Lev Tolstoj, Ed Garzanti 2012, traduzione Pietro Zveteremich
  2. Quiroz et al., Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease; Jama Neurology 2018
  3. Acosta Baena et al., Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer’s disease: a retrospective cohort study; The Lancet Neurology 2011
  4. Jack et al., Update on hypothetical model of Alzheimer’s disease biomarkers, The Lancet Neurology 2013
  5. Roberts et al., Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting, JAMA Neurology 2018

Capitolo 3 – I nuovi biomarcatori e l’importanza di una diagnosi precoce

  1. Jack et al., A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers, Neurology 2016
  2. Barthelemy et al., Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification, Alzheimer’s Research and therapy 2020
  3. Karikari et al., Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts, The Lancet Neurology 2020
  4. Ashton et al., Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology, Acta Neuropathologica 2020
  5. Alzheimer’s Disease International, World Alzheimer Report 2021 – Journey through the diagnosis of dementia, London 2021
  6. Fredericksen et al., European Academy of Neurology/European Alzheimer’s Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment, European Journal of Neurology 2020

Capitolo 4 – Ce l’ho nei geni?

  1. Discorso tenuto all’International Forum on Women’s Brain and Mental Health, Zurigo, 2019 (traduzione di Maria Teresa Ferretti). Ho raccontato la storia di Sofia e la sua malattia nel libro ‘Una bambina senza testa’ (Maria Teresa Ferretti, Antonella Santuccione Chadha, Ed. Edizioni Mondo Nuovo, 2021)
  2. https://www.bbc.com/news/world-latin-america-13428265
  3. https://eu.azcentral.com/story/news/local/best-reads/2015/02/15/alzheimers-research-colombia-curse-part-one/23373503/
  4. Arboleda-Velasquez JF, et al., Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019
  5. Hollongworth et al., Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease, Nature Genetics 2011
  6. Alina Solomon, et al., Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention, JAMA Neurology, 2018

Capitolo 5 – L’Alzheimer e le donne

  1. www.womensbrainproject.com
  2. Sex and Gender Differences in Alzheimer’s Disease, 2021, curato da Ferretti, Schumacher Dimech, Santuccione Chadha, Ed. Elsevier, 2021
  3. Alzheimer’s Association, 2021, Alzheimer’s Facts and Figures, 2021
  4. Chene et al., Gender and incidence of dementia in the Framingham Heart Study from mid-adult lifeAlzheimer’s and Dementia 2015
  5. Vogel et al., The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030; The Lancet 2021
  6. Ferretti-Martinkova, Sex and gender differences in Alzheimer’s disease: current challenges and implications for clinical practice, European Journal of Neurology, 2020
  7. Satizabal et al., Incidence of Dementia over Three Decades in the Framingham Heart Study; New England Journal of Medicine 2016
  8. Kivimaeki et al., Cognitive stimulation in the workplace, plasma proteins, and risk of dementia: three analyses of population cohort studies, British Medical Journal, 2021
  9. Sharma et al., Gender differences in caregiving among family – caregivers of people with mental illnesses; World Journal Psychiatry 2016
  10. Sundermann et al., Sex-specific norms for verbal memory tests may improve diagnostic accuracy of amnestic MCI, Neurology 2019
  11. Ferretti et al., Sex differences in Alzheimer disease — the gateway to precision medicine, Nature Reviews Neurology 2018

Capitolo 6 – Sintomi: non solo memoria

  1. Un’infografica chiara sui campanelli di allarme per la demenza: www.alzint.org
  2. Vogel, et al., Four distinct trajectories of tau deposition identified in Alzheimer’s disease. Nature Medicine 2021
  3. Hippius, The discovery of Alzheimer’s disease, Dialogues in Clinical Neuroscience 2003

Capitolo 7 – Una cura per l’Alzheimer

  1. Schenk et al., Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse, Nature, 1999
  2. La storia di vari studi clinici è riassunta bene, con tutti i riferimenti bibliografici, dal sito Alzforum. Qui il link per lo studio clinico AN1792
  3. https://www.alzforum.org/therapeutics/solanezumab
  4. Salloway et al., Incidence and clinical progression of placebo-treated amyloid-negative subjects with mild-to-moderate Alzheimer’s disease (AD): results from the phase III PET substudies of bapineuzumab and solanezumab. Alzheimer and Dementia 2013
  5. Rabinovici et al., Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia, Journal of the American Medical Association (JAMA) 2019
  6. Sevigny et al., The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease, Nature, 2016
  7. Boada et al., A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease: Primary results of the AMBAR Study, Alzheimer’s and Dementia 2020

Capitolo 8 – Una nuova speranza: prevenire è possibile 

  1. https://www.dementiaallianceinternational.org/tag/updates-in-precision-medicine-and-protocols-for-dementia/ (traduzione di Maria Teresa Ferretti)
  2. O’Keeffee et al., Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis, British Medical Journal (BMJ) 2018
  3. U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2020 submission data (1999-2018): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; www.cdc.gov/cancer/dataviz
  4. Livingstone et al., Dementia prevention, intervention, and care: 2020 report of the Lancet Commission, The Lancet 2020
  5. Ngandu et al., A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial, The Lancet 2015
  6. Morais et al., The gut microbiota–brain axis in behaviour and brain disorders, Nature Reviews Microbiology 2020
  7. World Health Organization, Risk reduction of cognitive decline and dementia: WHO guidelines, 2019

Capitolo 9 – I dodici fattori di rischio da controllare

  1. Livingstone et al., Dementia prevention, intervention, and care: 2020 report of the Lancet Commission, The Lancet 2020
  2. Satizabal et al., Incidence of Dementia over Three Decades in the Framingham Heart Study, the New England Journal of Medicine (NEJM) 2016
  3. Kivimäki et al., Cognitive stimulation in the workplace, plasma proteins, and risk of dementia: three analyses of population cohort studies, The British Medical Journal (BMJ) 2021
  4. The SPRINT-MIND Investigators for the SPRINT Research Group; Williamson et al., Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial, the Journal of the American medical association (JAMA) 2019
  5. Mackay et al., Neurodegenerative Disease Mortality among Former Professional Soccer Players, the New England Journal of Medicine (NEJM) 2019
  6. Ma et al., Higher risk of dementia in English older individuals who are overweight or obese, International Journal of Epidemilogy 2020
  7. Ngandu et al., A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial, The Lancet, 2015

Capitolo 10 – Il ruolo del paziente e dei famigliari

  1. Alzheimer’s Disease International, World Alzheimer Report 2019, Attitudes to dementia; London
  2. Alcuni utili consigli per affrontare le ‘fughe’ (www.alz.org/)
  3. https://www.aarp.org/caregiving/life-balance/info-2020/sandwich-generation-caregivers.html
  4. https://www.oecd.org/pensions/towards-improved-retirement-savings-outcomes-for-women-f7b48808-en.htm
  5. James Charlton, Nothing About Us Without Us: Disability Oppression and Empowerment, University of California Press, 27 Mar 1998
  6. Una valutazione dell’Agenzia Italiana del Farmaco sull’importanza degli esiti riferiti dai pazienti
  7. Solomon et al., Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention, the Journal of the American Medical Association (JAMA) Neurology, 2018

Capitolo 11 – Le nuove tecnologie e il futuro della medicina

  1. https://www.gatesnotes.com/Health/New-breakthroughs-in-Alzheimers-diagnostics (traduzione di Maria Teresa Ferretti)
  2. https://www.uswitch.com/mobiles/screentime-report/
  3. Do I sound sick? The Lancet Digital Health editorial, 2021
  4. Eyigoz et al., Linguistic markers predict onset of Alzheimer’s disease, E-Clinical Medicine 2020
  5. Coughlan et al., Toward personalized cognitive diagnostics of at-genetic-risk Alzheimer’s disease, Proceedings of the National Academy of Sciences (PNAS) 2019
  6. Buegler et al., Digital biomarker-based individualized prognosis for people at risk of dementia, Alzheimer’s and Dementia 2020
  7. Midaglia et al., Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study, Journal of Medical Internet Research 2019
  8. https://theconversation.com/would-your-mobile-phone-be-powerful-enough-to-get-you-to-the-moon-115933
  9. Reardon, Rise of Robot Radiologists, Nature 2019
  10. Van Maurik IS, et al. Personalized risk for clinical progression in cognitively normal subjects – The ABIDE project, Alzheimer’s Research and Therapeutics 2019

Conclusioni – La rivoluzione di tutti

  1. Social media, activism, trucker caps: the fascinating story behind long COVID
  2. Ho parlato per la prima volta di approccio democratico alla medicina nel mio TED-x: ‘Listen to one patient to help a million’